

CSD/NSE/2021-2022
March 24, 2022

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Increase in volume

Ref: NSE/CM/Surveillance/11725, your email dated 23rd March, 2022

.....

We write to inform that our company has been notifying NSE & BSE all the events, information that have a bearing on the operations/performance of the company which includes all price sensitive information, etc. that comes under the purview of Regulation 30 of SEBI (LODR) Regulations, 2015 from time to time.

At this point of time we do not have any material event due for notification to the stock exchanges under Regulation 30 of SEBI (LODR) Regulations. The increase in the price/volume of our security in the recent past appears to be based on market speculation and we have no other comment to offer on this development.

We request you to disseminate this clarification on your website for information of general public, which is also being uploaded on our Company's website.

Thanking you,
Yours faithfully,
For Suven Pharmaceuticals Limited



K. Hanumantha Rao
Company Secretary

Suven Pharmaceuticals Limited

Registered Office: # 8-2-334 I SDE Serene Chambers I 3rd Floor I Road No.5
Avenue 7 I Banjara Hills I Hyderabad - 500034 I Telangana I India I CIN: L24299TG2018PLC128171
Tel: 91 40 2354 9414 /1142 /3311 I Fax: 91 40 2354 1152 I Email: info@suvenpharm.com I www.suvenpharm.com